Translational Research in Oncology

  • Asma Saleem QaziEmail author
  • Samina Akbar
  • Rida Fatima Saeed
  • Muhammad Zeeshan BhattiEmail author


Cancer proteomics is a diverse and challenging field. It provides the promising tool that aids in the understanding of the disease, yet early-stage diagnosis is still a question and crucial for successful treatment of cancer. Genomics aided with proteomics has emerged as a larger platform for understanding the disease spread, proliferation, metastasis, genomic aberrations, mutational changes, therapeutics, design drug delivery system, proteomic anomalies, structural changes, and signaling pathways and moving toward personalized approach. Biomarker identification and development of the panel are very precious in cancer treatment. Generally, biomarker identification, validation, and clinical examination are specific tools for accurate diagnostic, prognostic, and therapeutics. Present-day advances in proteomics and computational sciences have opened a gateway for the identification and quantitative analysis of protein variations associated with the complexities and heterogeneity of tumor development. Concept of personalized medicine is an emerging approach for cancer patient treatment, yet it has many challenges to overcome before its clinical application. Translational research in oncology still needs lots of quality research to overcome many challenges and for improvement in biomedical application and cancer patient care.


Translational research Proteomic approaches Cancer biomarkers Risk assessment Personalized medicine Onco-proteomics Biomedical applications 


  1. 1.
    Naylor S (2003) Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn 3(5):525–5299. Scholar
  2. 2.
    Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1(2):182–188. Scholar
  3. 3.
    Wulfkuhle JD, Liotta LA, Petricoin EF (2003) Proteomic applications for the early detection of cancer. Nat Rev Cancer 3(4):267–275. Scholar
  4. 4.
    Hudler P, Kocevar N, Komel R (2014) Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics. Sci World J 2014:260348. Scholar
  5. 5.
    Henry NL, Hayes DF (2012) Cancer biomarkers. Mol Oncol 6(2):140–146. Scholar
  6. 6.
    Zhang Z, Chan DW (2005) Cancer proteomics: in pursuit of “true” biomarker discovery. Cancer Epidemiol Biomarkers Prev 14(10):2283–2286. Scholar
  7. 7.
    Srinivasan R (1986) Ablation of polymers and biological tissue by ultraviolet lasers. Science 234(4776):559–565. Scholar
  8. 8.
    Han Y, Gu Y, Zhang AC, Lo YH (2016) Review: imaging technologies for flow cytometry. Lab Chip 16(24):4639–4647. Scholar
  9. 9.
    Srinivas PR, Srivastava S, Hanash S, Wright GL Jr (2001) Proteomics in early detection of cancer. Clin Chem 47(10):1901–1911CrossRefGoogle Scholar
  10. 10.
    Croce CM (2008) Oncogenes and cancer. N Engl J Med 358(5):502–511. Scholar
  11. 11.
    Li X, Blount PL, Vaughan TL, Reid BJ (2011) Application of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view. PLoS Comput Biol 7(2):e1001087. Scholar
  12. 12.
    Goncalves A, Esterni B, Bertucci F, Sauvan R, Chabannon C, Cubizolles M, Bardou VJ, Houvenaegel G, Jacquemier J, Granjeaud S, Meng XY, Fung ET, Birnbaum D, Maraninchi D, Viens P, Borg JP (2006) Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25(7):981–989. Scholar
  13. 13.
    Li X, Galipeau PC, Sanchez CA, Blount PL, Maley CC, Arnaudo J, Peiffer DA, Pokholok D, Gunderson KL, Reid BJ (2008) Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett’s esophagus neoplastic progression. Cancer Prev Res (Phila) 1(6):413–423. Scholar
  14. 14.
    Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O’Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR (2007) Patterns of somatic mutation in human cancer genomes. Nature 446(7132):153–158. Scholar
  15. 15.
    Baudis M (2007) Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer 7:226. Scholar
  16. 16.
    Litzenburger UM, Buenrostro JD, Wu B, Shen Y, Sheffield NC, Kathiria A, Greenleaf WJ, Chang HY (2017) Single-cell epigenomic variability reveals functional cancer heterogeneity. Genome Biol 18(1):15. Scholar
  17. 17.
    Wang X, Markowetz F, De Sousa EMF, Medema JP, Vermeulen L (2013) Dissecting cancer heterogeneity--an unsupervised classification approach. Int J Biochem Cell Biol 45(11):2574–2579. Scholar
  18. 18.
    Gustafsson OJ, Eddes JS, Meding S, McColl SR, Oehler MK, Hoffmann P (2013) Matrix-assisted laser desorption/ionization imaging protocol for in situ characterization of tryptic peptide identity and distribution in formalin-fixed tissue. Rapid Commun Mass Spectrom 27(6):655–670. Scholar
  19. 19.
    Meding S, Martin K, Gustafsson OJ, Eddes JS, Hack S, Oehler MK, Hoffmann P (2013) Tryptic peptide reference data sets for MALDI imaging mass spectrometry on formalin-fixed ovarian cancer tissues. J Proteome Res 12(1):308–315. Scholar
  20. 20.
    Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P (2014) Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer 111(6):1201–1212. Scholar
  21. 21.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. Scholar
  22. 22.
    Corbo C, Cevenini A, Salvatore F (2017) Biomarker discovery by proteomics-based approaches for early detection and personalized medicine in colorectal cancer. Proteomics Clin Appl 11(5–6).
  23. 23.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. Scholar
  24. 24.
    Lee JY, Yoon JK, Kim B, Kim S, Kim MA, Lim H, Bang D, Song YS (2015) Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing. BMC Cancer 15:85. Scholar
  25. 25.
    Mabert K, Cojoc M, Peitzsch C, Kurth I, Souchelnytskyi S, Dubrovska A (2014) Cancer biomarker discovery: current status and future perspectives. Int J Radiat Biol 90(8):659–677. Scholar
  26. 26.
    Sever R, Brugge JS (2015) Signal transduction in cancer. Cold Spring Harb Perspect Med 5(4).
  27. 27.
    Monica L, Savu L (2013) A different approach for cellular oncogene identification came from Drosophila genetics. In: Oncogene and cancer - from bench to clinic.
  28. 28.
    Yan H, Chen X, Li Y, Fan L, Tai Y, Zhou Y, Chen Y, Qi X, Huang R, Ren J (2019) MiR-1205 functions as a tumor suppressor by disconnecting the synergy between KRAS and MDM4/E2F1 in non-small cell lung cancer. Vaccine 9(2):312–329Google Scholar
  29. 29.
    Albertson DG, Collins C, McCormick F, Gray JW (2003) Chromosome aberrations in solid tumors. Nat Genet 34(4):369–376. Scholar
  30. 30.
    Sauter ER (2017) Exosomes in blood and cancer. Transl Cancer Res 6(S8):S1316–S1320. Scholar
  31. 31.
    Aaltonen L, Johns L, Jarvinen H, Mecklin JP, Houlston R (2007) Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res 13(1):356–361. Scholar
  32. 32.
    Walker JG, Licqurish S, Chiang PP, Pirotta M, Emery JD (2015) Cancer risk assessment tools in primary care: a systematic review of randomized controlled trials. Ann Fam Med 13(5):480–489. Scholar
  33. 33.
    Yarnall JM, Crouch DJ, Lewis CM (2013) Incorporating non-genetic risk factors and behavioural modifications into risk prediction models for colorectal cancer. Cancer Epidemiol 37(3):324–329. Scholar
  34. 34.
    Services USDoHaH (2014) The Colorectal Cancer Risk Assessment Tool. National Institutes of HealthGoogle Scholar
  35. 35.
    Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886. Scholar
  36. 36.
    Wang W, Niendorf KB, Patel D, Blackford A, Marroni F, Sober AJ, Parmigiani G, Tsao H (2010) Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res 70(2):552–559. Scholar
  37. 37.
    Wilson KE, Ryan MM, Prime JE, Pashby DP, Orange PR, O’Beirne G, Whateley JG, Bahn S, Morris CM (2004) Functional genomics and proteomics: application in neurosciences. J Neurol Neurosurg Psychiatry 75(4):529–538. Scholar
  38. 38.
    Kellner R (2000) Proteomics. Concepts and perspectives. Fresenius J Anal Chem 366:517–524CrossRefGoogle Scholar
  39. 39.
    Klein JB, Thongboonkerd V (2004) Overview of proteomics. Contrib Nephrol 141:1–10PubMedGoogle Scholar
  40. 40.
    Ullrich B, Ushkaryov YA, Südhof TC (1995) Cartography of neurexins: more than 1000 isoforms generated by alternative splicing and expressed in distinct subsets of neurons. Neuron 14(3)Google Scholar
  41. 41.
    Shruthi BS, Vinodhkumar P, Selvamani (2016) Proteomics: a new perspective for cancer. Adv Biomed Res 5:67. Scholar
  42. 42.
    Carr KM, Rosenblatt K, Petricoin EF, Liotta LA (2004) Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum Genomics 1(2):134–140CrossRefGoogle Scholar
  43. 43.
    Vaezzadeh AR, Steen H, Freeman MR, Lee RS (2009) Proteomics and opportunities for clinical translation in urological disease. J Urol 182(3):835–843. Scholar
  44. 44.
    Liotta LA, Kohn EC, Petricoin EF (2001) Clinical proteomics. JAMA 286(18).
  45. 45.
    Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306):572–577. Scholar
  46. 46.
    Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW (2002) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48(8):1296–1304CrossRefGoogle Scholar
  47. 47.
    Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62(13):3609–3614PubMedGoogle Scholar
  48. 48.
    Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, Lee CC, Leung TW, Ho SK, Johnson PJ (2003) Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49(5):752–760CrossRefGoogle Scholar
  49. 49.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. Scholar
  50. 50.
    Sung HJ, Cho JY (2008) Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 41(9):615–625. Scholar
  51. 51.
    Luo L, Dong LY, Yan QG, Cao SJ, Wen XT, Huang Y, Huang XB, Wu R, Ma XP (2014) Research progress in applying proteomics technology to explore early diagnosis biomarkers of breast cancer, lung cancer and ovarian cancer. Asian Pac J Cancer Prev 15(20):8529–8538. Scholar
  52. 52.
    Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM (2001) An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 98(17):9824–9829. Scholar
  53. 53.
    Zamay TN, Zamay GS, Kolovskaya OS, Zukov RA, Petrova MM, Gargaun A, Berezovski MV, Kichkailo AS (2017) Current and prospective protein biomarkers of lung cancer. Cancers (Basel) 9(11).
  54. 54.
    Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faca VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, Depinho RA, Kemp CJ, Varmus HE, Hanash SM (2011) Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 20(3):289–299. Scholar
  55. 55.
    Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE 2nd (2007) Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25(35):5578–5583. Scholar
  56. 56.
    Cheung CHY, Juan HF (2017) Quantitative proteomics in lung cancer. J Biomed Sci 24(1):37. Scholar
  57. 57.
    Wu CC, Chien KY, Tsang NM, Chang KP, Hao SP, Tsao CH, Chang YS, Yu JS (2005) Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 5(12):3173–3182. Scholar
  58. 58.
    Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF Jr, Hampton GM (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 100(6):3410–3415. Scholar
  59. 59.
    Huang LJ, Chen SX, Huang Y, Luo WJ, Jiang HH, Hu QH, Zhang PF, Yi H (2006) Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. Lung Cancer 54(1):87–94. Scholar
  60. 60.
    Conrad DH, Goyette J, Thomas PS (2008) Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 23(Suppl 1):78–84. Scholar
  61. 61.
    Polanski M, Anderson NL (2007) A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 1:1–48PubMedPubMedCentralGoogle Scholar
  62. 62.
    Sallam RM (2015) Proteomics in cancer biomarkers discovery: challenges and applications. Dis Markers 2015:321370. Scholar
  63. 63.
    Geiger T, Madden SF, Gallagher WM, Cox J, Mann M (2012) Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res 72(9):2428–2439. Scholar
  64. 64.
    Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, Nelson PS, Hanash SM, Kemp CJ (2011) Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 71(15):5090–5100. Scholar
  65. 65.
    Luftner D, Possinger K (2002) Nuclear matrix proteins as biomarkers for breast cancer. Expert Rev Mol Diagn 2(1):23–31. Scholar
  66. 66.
    Samadder NJ, Jasperson K, Burt RW (2015) Hereditary and common familial colorectal cancer: evidence for colorectal screening. Dig Dis Sci 60(3):734–747. Scholar
  67. 67.
    Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa EMF, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21(11):1350–1356. Scholar
  68. 68.
    Chauvin A, Boisvert FM (2018) Clinical proteomics in colorectal cancer, a promising tool for improving personalised medicine. Proteomes 6(4).
  69. 69.
    Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S, Davies SR, Wang S, Wang P, Kinsinger CR, Rivers RC, Rodriguez H, Townsend RR, Ellis MJ, Carr SA, Tabb DL, Coffey RJ, Slebos RJ, Liebler DC, Nci C (2014) Proteogenomic characterization of human colon and rectal cancer. Nature 513(7518):382–387. Scholar
  70. 70.
    Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, Masucci GV, Robbins PB, Selvan SR, Streicher HZ, Zhang J, Butterfield LH, Thurin M (2016) Validation of biomarkers to predict response to immunotherapy in cancer: volume II - clinical validation and regulatory considerations. J Immunother Cancer 4:77. Scholar
  71. 71.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35):5705–5712. Scholar
  72. 72.
    Takano M, Sugiyama T (2017) UGT1A1 polymorphisms in cancer: impact on irinotecan treatment. Pharmgenomics Pers Med 10:61–68. Scholar
  73. 73.
    Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A, Dylag T, Ehrich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung HY, Maahs D, Magni F, Manns MP, Manolis E, Mayer G, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP, Vlahou A (2012) Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 42(9):1027–1036. Scholar
  74. 74.
    Jennings L, Van Deerlin VM, Gulley ML, College of American Pathologists Molecular Pathology Resource C (2009) Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med 133(5):743–755. Scholar
  75. 75.
    Duffy MJ, O’Donovan N, Crown J (2011) Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 37(2):151–159. Scholar
  76. 76.
    Hoffman RM (2011) Clinical practice. Screening for prostate cancer. N Engl J Med 365(21):2013–2019. Scholar
  77. 77.
    Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM (2005) Autoantibody signatures in prostate cancer. N Engl J Med 353(12):1224–1235. Scholar
  78. 78.
    Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF, Emmert-Buck MR (2000) Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21(11):2235–2242.<2235::Aid-elps2235>3.0.Co;2-aCrossRefPubMedGoogle Scholar
  79. 79.
    Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, Sesterhenn IA, Conrads TP, Veenstra TD, Krizman DB (2005) Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics 4(11):1741–1753. Scholar
  80. 80.
    Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, van der Kwast T, Mizokami A, Morrissey C, Jarvi K, Diamandis EP (2013) Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol Cell Proteomics 12(6):1589–1601. Scholar
  81. 81.
    Cho WC (2014) Proteomics in translational cancer research: biomarker discovery for clinical applications. Expert Rev Proteomics 11(2):131–133. Scholar
  82. 82.
    He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu JF (2004) Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 4(10):3276–3287. Scholar
  83. 83.
    Altieri F, Di Stadio CS, Severino V, Sandomenico A, Minopoli G, Miselli G, Di Maro A, Ruvo M, Chambery A, Quagliariello V, Masullo M, Rippa E, Arcari P (2014) Anti-amyloidogenic property of human gastrokine 1. Biochimie 106:91–100. Scholar
  84. 84.
    Menheniott TR, Peterson AJ, O’Connor L, Lee KS, Kalantzis A, Kondova I, Bontrop RE, Bell KM, Giraud AS (2010) A novel gastrokine, Gkn3, marks gastric atrophy and shows evidence of adaptive gene loss in humans. Gastroenterology 138(5):1823–1835. Scholar
  85. 85.
    Lin LL, Huang HC, Juan HF (2012) Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics 75(11):3081–3097. Scholar
  86. 86.
    Jang JSJ, Cho HY, Lee YJ, Ha WS, Kim HW (2004) The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res Featuring Preclin Clin Cancer Ther 14(10):491–499. Scholar
  87. 87.
    Melle C, Ernst G, Schimmel B, Bleul A, Kaufmann R, Hommann M, Richter KK, Daffner W, Settmacher U, Claussen U, von Eggeling F (2005) Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. J Proteome Res 4(5):1799–1804. Scholar
  88. 88.
    Hao Y, Yu Y, Wang L, Yan M, Ji J, Qu Y, Zhang J, Liu B, Zhu Z (2008) IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. J Proteome Res 7(9):3668–3677. Scholar
  89. 89.
    Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM, Morgan TR, Ghany MG, Gretch DR, the H-CTG (2005) Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 43(3):434–441. Scholar
  90. 90.
    Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B (1984) Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310(22):1427–1431. Scholar
  91. 91.
    Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, Montorsi M, Torzilli G, Tommasini M, Terracciano L, Tornillo L, Vecchione R, Roncalli M (2007) Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45(3):725–734. Scholar
  92. 92.
    Wu Z, Pang W, Coghill GM (2015) An integrative top-down and bottom-up qualitative model construction framework for exploration of biochemical systems. Soft Comput 19(6):1595–1610. Scholar
  93. 93.
    Megger DA, Naboulsi W, Meyer HE, Sitek B (2014) Proteome analyses of hepatocellular carcinoma. J Clin Transl Hepatol 2(1):23–30. Scholar
  94. 94.
    Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, Hirohashi S (2004) Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 40(3):609–617. Scholar
  95. 95.
    Fu WM, Zhang JF, Wang H, Tan HS, Wang WM, Chen SC, Zhu X, Chan TM, Tse CM, Leung KS, Lu G, Xu HX, Kung HF (2012) Apoptosis induced by 1,3,6,7-tetrahydroxyxanthone in Hepatocellular carcinoma and proteomic analysis. Apoptosis 17(8):842–851. Scholar
  96. 96.
    Zhang J, Niu D, Sui J, Ching CB, Chen WN (2009) Protein profile in hepatitis B virus replicating rat primary hepatocytes and HepG2 cells by iTRAQ-coupled 2-D LC-MS/MS analysis: insights on liver angiogenesis. Proteomics 9(10):2836–2845. Scholar
  97. 97.
    Albrethsen J, Miller LM, Novikoff PM, Angeletti RH (2011) Gel-based proteomics of liver cancer progression in rat. Biochim Biophys Acta 1814(10):1367–1376. Scholar
  98. 98.
    Jain KK (2008) Innovations, challenges and future prospects of oncoproteomics. Mol Oncol 2(2):153–160. Scholar
  99. 99.
    Braoudaki M, Lambrou GI, Vougas K, Karamolegou K, Tsangaris GT, Tzortzatou-Stathopoulou F (2013) Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner. J Hematol Oncol 6:52. Scholar
  100. 100.
    Prada-Arismendy J, Arroyave JC, Rothlisberger S (2017) Molecular biomarkers in acute myeloid leukemia. Blood Rev 31(1):63–76. Scholar
  101. 101.
    Hjelle SM, Forthun RB, Haaland I, Reikvam H, Sjoholt G, Bruserud O, Gjertsen BT (2010) Clinical proteomics of myeloid leukemia. Genome Med 2(6):41. Scholar
  102. 102.
    Lopez-Pedrera C, Villalba JM, Siendones E, Barbarroja N, Gomez-Diaz C, Rodriguez-Ariza A, Buendia P, Torres A, Velasco F (2006) Proteomic analysis of acute myeloid leukemia: identification of potential early biomarkers and therapeutic targets. Proteomics 6(Suppl 1):S293–S299. Scholar
  103. 103.
    Voss T, Ahorn H, Haberl P, Döhner H, Wilgenbus K (2001) Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. Int J Cancer 91(2):180–186.<::Aid-ijc1037>3.0.Co;2-jCrossRefPubMedGoogle Scholar
  104. 104.
    Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Lowenberg B, Valk PJM (2018) Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 378(13):1189–1199. Scholar
  105. 105.
    Bai J, He A, Huang C, Yang J, Zhang W, Wang J, Yang Y, Zhang P, Zhang Y, Zhou F (2014) Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia. Proteome Sci 12(1):49. Scholar
  106. 106.
    Odreman F, Vindigni M, Gonzales ML, Niccolini B, Candiano G, Zanotti B, Skrap M, Pizzolitto S, Stanta G, Vindigni A (2005) Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 4(3):698–708. Scholar
  107. 107.
    Hu Y, Huang X, Chen GYJ, Yao SQ (2004) Recent advances in gel-based proteome profiling techniques. Mol Biotechnol 28(1):63–76. Scholar
  108. 108.
    Iwadate Y, Sakaida T, Hiwasa T, Nagai Y, Ishikura H, Takiguchi M, Yamaura A (2004) Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 64(7):2496–2501. Scholar
  109. 109.
    Liu H, Sadygov RG, Yates JR 3rd (2004) A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 76(14):4193–4201. Scholar
  110. 110.
    Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3(12):1154–1169. Scholar
  111. 111.
    Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH (1999) Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353(9160):1207–1210. Scholar
  112. 112.
    Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA (2001) Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 82(1):40–48. Scholar
  113. 113.
    Conrads TP, Zhou M, Petricoin EF III, Liotta L, Veenstra TD (2003) Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn 3(4):411–420CrossRefGoogle Scholar
  114. 114.
    Plebani M (2005) Proteomics: the next revolution in laboratory medicine? Clin Chim Acta 357(2):113–122. Scholar
  115. 115.
    Diamandis EP (2003) Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 49(8):1272–1275. Scholar
  116. 116.
    Lin YW, Lin CY, Lai HC, Chiou JY, Chang CC, Yu MH, Chu TY (2006) Plasma proteomic pattern as biomarkers for ovarian cancer. Int J Gynecol Cancer 16(Suppl 1):139–146. Scholar
  117. 117.
    Petricoin E (2003) The vision for a new diagnostic paradigm. Clin Chem 49(8):1276–1278. Scholar
  118. 118.
    Green CL, Khavari PA (2004) Targets for molecular therapy of skin cancer. Semin Cancer Biol 14(1):63–69. Scholar
  119. 119.
    Kasparian NA, McLoone JK, Meiser B (2009) Skin cancer-related prevention and screening behaviors: a review of the literature. J Behav Med 32(5):406–428. Scholar
  120. 120.
    Franssen ME, Zeeuwen PL, Vierwinden G, van de Kerkhof PC, Schalkwijk J, van Erp PE (2005) Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis. J Invest Dermatol 124(2):373–383. Scholar
  121. 121.
    Huang CM, Foster KW, DeSilva T, Zhang J, Shi Z, Yusuf N, Van Kampen KR, Elmets CA, Tang DC (2003) Comparative proteomic profiling of murine skin. J Invest Dermatol 121(1):51–64. Scholar
  122. 122.
    Hamideh MF, Hakimeh Z, Mostafa RT, Parviz T (2010) Roteomic analysis of gene expression in basal cell carcinoma. Iran J Dermatol 13(4):112–117Google Scholar
  123. 123.
    Cheng SL, Liu RH, Sheu JN, Chen ST, Sinchaikul S, Tsay GJ (2007) Toxicogenomics of A375 human malignant melanoma cells treated with arbutin. J Biomed Sci 14(1):87–105. Scholar
  124. 124.
    Penque D (2009) Two-dimensional gel electrophoresis and mass spectrometry for biomarker discovery. Proteomics Clin Appl 3(2):155–172. Scholar
  125. 125.
    Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, Mehigh RJ, Cockrill SL, Scott GB, Tammen H, Schulz-Knappe P, Speicher DW, Vitzthum F, Haab BB, Siest G, Chan DW (2005) HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5(13):3262–3277. Scholar
  126. 126.
    Aebersold R, Burlingame AL, Bradshaw RA (2013) Western blots versus selected reaction monitoring assays: time to turn the tables? Mol Cell Proteomics 12(9):2381–2382. Scholar
  127. 127.
    Elschenbroich S, Ignatchenko V, Clarke B, Kalloger SE, Boutros PC, Gramolini AO, Shaw P, Jurisica I, Kislinger T (2011) In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. J Proteome Res 10(5):2286–2299. Scholar
  128. 128.
    Anderson NL, Matheson AD, Steiner S (2000) Proteomics: applications in basic and applied biology. Curr Opin Biotechnol 11(4):408–412. Scholar
  129. 129.
    Welch DR, McClure SA, Aeed PA, Bahner MJ, Adams LD (1990) Tumor progression- and metastasis-associated proteins identified using a model of locally recurrent rat mammary adenocarcinomas. Clin Exp Metastasis 8(6):533–551. Scholar
  130. 130.
    Sarto C, Marocchi A, Sanchez JC, Giannone D, Frutiger S, Golaz O, Wilkins MR, Doro G, Cappellano F, Hughes G, Hochstrasser DF, Mocarelli P (1997) Renal cell carcinoma and normal kidney protein expression. Electrophoresis 18(3–4):599–604. Scholar
  131. 131.
    Alaiya AA, Franzén B, Fujioka K, Moberger B, Schedvins K, Silfversvärd C, Linder S, Auer G (1997) Phenotypic analysis of ovarian carcinoma: polypeptide expression in benign, borderline and malignant tumors. Int J Cancer 73(5):678–682.<678::Aid-ijc11>3.0.Co;2-2CrossRefPubMedGoogle Scholar
  132. 132.
    Franzen B, Linder S, Uryu K, Alaiya AA, Hirano T, Kato H, Auer G (1996) Expression of tropomyosin isoforms in benign and malignant human breast lesions. Br J Cancer 73(7):909–913. Scholar
  133. 133.
    Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM (2001) Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 7(4):493–496. Scholar
  134. 134.
    Bergman A-C, Benjamin T, Alaiya A, Waltham M, Sakaguchi K, Franzén B, Linder S, Bergman T, Auer G, Appella E, Wirth PJ, Jörnvall H (2000) Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 21(3):679–686.<679::Aid-elps679>3.0.Co;2-aCrossRefPubMedGoogle Scholar
  135. 135.
    Wright GL Jr, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, Schellhammer PF, Gong L, Vlahou A (1999) Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 2(5-6):264–276. Scholar
  136. 136.
    Paweletz CP, Gillespie JW, Ornstein DK, Simone NL, Brown MR, Cole KA, Wang Q-H, Huang J, Hu N, Yip T-T, Rich WE, Kohn EC, Linehan WM, Weber T, Taylor P, Emmert-Buck MR, Liotta LA, Petricoin EF (2000) Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev Res 49(1):34–42.<34::Aid-ddr6>3.0.Co;2-wCrossRefGoogle Scholar
  137. 137.
    Sadikovic B, Al-Romaih K, Squire JA, Zielenska M (2008) Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics 9(6):394–408. Scholar
  138. 138.
    Cho WC (2007) Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 6:25. Scholar
  139. 139.
    Krueger KE, Srivastava S (2006) Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteomics 5(10):1799–1810. Scholar
  140. 140.
    Kolch W, Pitt A (2010) Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer 10(9):618–629. Scholar
  141. 141.
    Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353(19):2012–2024. Scholar
  142. 142.
    Darie CC (2013) Mass spectrometry and proteomics: principle, workflow, challenges and perspectives. Mod Chem Appl 01(02).
  143. 143.
    Swaney DL, Villen J (2016) Proteomic analysis of protein posttranslational modifications by mass spectrometry. Cold Spring Harb Protoc 2016 (3):pdb top077743.
  144. 144.
    Tainsky MA (2009) Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim Biophys Acta 1796(2):176–193. Scholar
  145. 145.
    Tyers M, Mann M (2003) From genomics to proteomics. Nature 422(6928):193–197. Scholar
  146. 146.
    Gulati S, Cheng TM, Bates PA (2013) Cancer networks and beyond: interpreting mutations using the human interactome and protein structure. Semin Cancer Biol 23(4):219–226. Scholar
  147. 147.
    Aebersold R, Cravatt BF (2002) Proteomics – advances, applications and the challenges that remain. Trends Biotechnol 20(12):s1–s2. Scholar
  148. 148.
    Davalieva K, Polenakovic M (2015) Proteomics in diagnosis of prostate cancer. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 36(1):5–36Google Scholar
  149. 149.
    Faria SS, Morris CF, Silva AR, Fonseca MP, Forget P, Castro MS, Fontes W (2017) A timely shift from shotgun to targeted proteomics and how it can be groundbreaking for cancer research. Front Oncol 7:13. Scholar
  150. 150.
    Clauser KR, Hall SC, Smith DM, Webb JW, Andrews LE, Tran HM, Epstein LB, Burlingame AL (1995) Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. Proc Natl Acad Sci U S A 92(11):5072–5076. Scholar
  151. 151.
    Ang CS, Rothacker J, Patsiouras H, Gibbs P, Burgess AW, Nice EC (2011) Use of multiple reaction monitoring for multiplex analysis of colorectal cancer-associated proteins in human feces. Electrophoresis 32(15):1926–1938. Scholar
  152. 152.
    Milioli HH, Vimieiro R, Riveros C, Tishchenko I, Berretta R, Moscato P (2015) The discovery of novel biomarkers improves breast cancer intrinsic subtype prediction and reconciles the labels in the METABRIC data set. PLoS One 10(7):e0129711. Scholar
  153. 153.
    Chen J, Wu W, Chen L, Zhou H, Yang R, Hu L, Zhao Y (2013) Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein. Pancreatology 13(3):290–297. Scholar
  154. 154.
    Guo L, Zhang C, Zhu J, Yang Y, Lan J, Su G, Xie X (2016) Proteomic identification of predictive tissue biomarkers of sensitive to neoadjuvant chemotherapy in squamous cervical cancer. Life Sci 151:102–108. Scholar
  155. 155.
    Mesri M (2014) Advances in proteomic technologies and its contribution to the field of cancer. Adv Med 2014:238045. Scholar
  156. 156.
    Milioli HH, Santos Sousa K, Kaviski R, Dos Santos Oliveira NC, De Andrade Urban C, De Lima RS, Cavalli IJ, De Souza Fonseca Ribeiro EM (2015) Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion. Cancer Genomics Proteomics 12(2):89–101PubMedGoogle Scholar
  157. 157.
    Longsworth LG, Shedlovsky T, Macinnes DA (1939) Electrophoretic patterns of normal and pathological human blood serum and plasma. J Exp Med 70(4):399–413. Scholar
  158. 158.
    Di Girolamo F, Del Chierico F, Caenaro G, Lante I, Muraca M, Putignani L (2012) Human serum proteome analysis: new source of markers in metabolic disorders. Biomark Med 6(6):759–773. Scholar
  159. 159.
    O’Farrell PH (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250(10):4007–4021PubMedPubMedCentralGoogle Scholar
  160. 160.
    Norbeck J, Blomberg A (1997) Two-dimensional electrophoretic separation of yeast proteins using a non-linear wide range (pH 3–10) immobilized pH gradient in the first dimension; reproducibility and evidence for isoelectric focusing of alkaline (pI >7) proteins. Yeast 13(16):1519–1534.<1519::Aid-yea211>3.0.Co;2-uCrossRefPubMedGoogle Scholar
  161. 161.
    Doustjalali SR, Yusof R, Govindasamy GK, Bustam AZ, Pillay B, Hashim OH (2006) Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression. J Med Invest 53(1,2):20–28. Scholar
  162. 162.
    Oestergaard M, Wolf H, Oerntoft TF, Celis JE (1999) Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis 20(2):349–354.<349::Aid-elps349>3.0.Co;2-bCrossRefGoogle Scholar
  163. 163.
    Jungblut PR, Zimny-Arndt U, Zeindl-Eberhart E, Stulik J, Koupilova K, Pleißner K-P, Otto A, Müller E-C, Sokolowska-Köhler W, Grabher G, Stöffler G (1999) Proteomics in human disease: cancer, heart and infectious diseases. Electrophoresis 20(10):2100–2110.<2100::Aid-elps2100>3.0.Co;2-dCrossRefPubMedGoogle Scholar
  164. 164.
    Chevalier F (2010) Highlights on the capacities of “Gel-based” proteomics. Proteome Sci 8:23. Scholar
  165. 165.
    Unlu M, Morgan ME, Minden JS (1997) Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18(11):2071–2077. Scholar
  166. 166.
    Zhang B, Barekati Z, Kohler C, Radpour R, Asadollahi R, Holzgreve W, Zhong XY (2010) Proteomics and biomarkers for ovarian cancer diagnosis. Ann Clin Lab Sci 40(3):218–225PubMedGoogle Scholar
  167. 167.
    Karp NA, Feret R, Rubtsov DV, Lilley KS (2008) Comparison of DIGE and post-stained gel electrophoresis with both traditional and SameSpots analysis for quantitative proteomics. Proteomics 8(5):948–960. Scholar
  168. 168.
    Gharbi S, Gaffney P, Yang A, Zvelebil MJ, Cramer R, Waterfield MD, Timms JF (2002) Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics 1(2):91–98. Scholar
  169. 169.
    Gade D, Thiermann J, Markowsky D, Rabus R (2003) Evaluation of two-dimensional difference gel electrophoresis for protein profiling. Soluble proteins of the marine bacterium Pirellula sp. strain 1. J Mol Microbiol Biotechnol 5(4):240–251. Scholar
  170. 170.
    Shaw J, Rowlinson R, Nickson J, Stone T, Sweet A, Williams K, Tonge R (2003) Evaluation of saturation labelling two-dimensional difference gel electrophoresis fluorescent dyes. Proteomics 3(7):1181–1195. Scholar
  171. 171.
    Zhou G, Li H, DeCamp D, Chen S, Shu H, Gong Y, Flaig M, Gillespie JW, Hu N, Taylor PR, Emmert-Buck MR, Liotta LA, Petricoin EF, Zhao Y (2002) 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 1(2):117–123. Scholar
  172. 172.
    Govorun VM, Archakov AI (2002) Proteomic technologies in modern biomedical science. Biochemistry (Mosc) 67(10):1109–1123CrossRefGoogle Scholar
  173. 173.
    Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA (2002) Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 1:683. Scholar
  174. 174.
    Chen EI, Yates JR 3rd (2007) Cancer proteomics by quantitative shotgun proteomics. Mol Oncol 1(2):144–159. Scholar
  175. 175.
    Bouwman K, Qiu J, Zhou H, Schotanus M, Mangold LA, Vogt R, Erlandson E, Trenkle J, Partin AW, Misek D, Omenn GS, Haab BB, Hanash S (2003) Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 3(11):2200–2207. Scholar
  176. 176.
    Charboneau L, Tory H, Chen T, Winters M, Petricoin EF 3rd, Liotta LA, Paweletz CP (2002) Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic 1(3):305–315CrossRefGoogle Scholar
  177. 177.
    Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF 3rd, Wulfkuhle JD (2005) Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4(4):346–355. Scholar
  178. 178.
    Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, Petricoin EF 3rd (2003) Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3(11):2085–2090. Scholar
  179. 179.
    Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, Liotta LA (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20(16):1981–1989. Scholar
  180. 180.
    Pereira-Faca SR, Kuick R, Puravs E, Zhang Q, Krasnoselsky AL, Phanstiel D, Qiu J, Misek DE, Hinderer R, Tammemagi M, Landi MT, Caporaso N, Pfeiffer R, Edelstein C, Goodman G, Barnett M, Thornquist M, Brenner D, Hanash SM (2007) Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res 67(24):12000–12006. Scholar
  181. 181.
    Anderson L, Hunter CL (2006) Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 5(4):573–588. Scholar
  182. 182.
    Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP (2003) Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A 100(12):6940–6945. Scholar
  183. 183.
    Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM (2007) Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci U S A 104(14):5860–5865. Scholar
  184. 184.
    Yates JR (1998) Mass spectrometry and the age of the proteome. J Mass Spectrom 33(1):1–19.<1::Aid-jms624>3.0.Co;2-9CrossRefPubMedGoogle Scholar
  185. 185.
    Timmins-Schiffman E, Nunn BL, Goodlett DR, Roberts SB (2013) Shotgun proteomics as a viable approach for biological discovery in the Pacific oyster. Conserv Physiol 1(1):cot009. Scholar
  186. 186.
    Abdallah C, Dumas-Gaudot E, Renaut J, Sergeant K (2012) Gel-based and gel-free quantitative proteomics approaches at a glance. Int J Plant Genomics 2012:494572. Scholar
  187. 187.
    Zhang Y, Fonslow BR, Shan B, Baek MC, Yates JR 3rd (2013) Protein analysis by shotgun/bottom-up proteomics. Chem Rev 113(4):2343–2394. Scholar
  188. 188.
    Nwabo Kamdje AH, Seke Etet PF, Vecchio L, Muller JM, Krampera M, Lukong KE (2014) Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal 26(12):2843–2856. Scholar
  189. 189.
    Wiesner A (2004) Detection of tumor markers with ProteinChip® technology. Curr Pharm Biotechnol 5(1):45–67. Scholar
  190. 190.
    Hu Y, Zhang S, Yu J, Liu J, Zheng S (2005) SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 14(4):250–255. Scholar
  191. 191.
    Nomura DK, Dix MM, Cravatt BF (2010) Activity-based protein profiling for biochemical pathway discovery in cancer. Nat Rev Cancer 10(9):630–638. Scholar
  192. 192.
    Sadaghiani AM, Verhelst SH, Bogyo M (2007) Tagging and detection strategies for activity-based proteomics. Curr Opin Chem Biol 11(1):20–28. Scholar
  193. 193.
    Fonovic M, Bogyo M (2008) Activity-based probes as a tool for functional proteomic analysis of proteases. Expert Rev Proteomics 5(5):721–730. Scholar
  194. 194.
    Karas M, Bahr U, Dülcks T (2000) Nano-electrospray ionization mass spectrometry: addressing analytical problems beyond routine. Fresenius J Anal Chem 366(6-7):669–676. Scholar
  195. 195.
    Abo M, Li C, Weerapana E (2018) Isotopically-labeled iodoacetamide-alkyne probes for quantitative cysteine-reactivity profiling. Mol Pharm 15(3):743–749. Scholar
  196. 196.
    Ardito F, Giuliani M, Perrone D, Troiano G, Lo Muzio L (2017) The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int J Mol Med 40(2):271–280. Scholar
  197. 197.
    Yarden Y (2001) The EGFR family and its ligands in human cancer. Eur J Cancer 37:3–8. Scholar
  198. 198.
    Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD, Comb MJ (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23(1):94–101. Scholar
  199. 199.
    Chi A, Huttenhower C, Geer LY, Coon JJ, Syka JE, Bai DL, Shabanowitz J, Burke DJ, Troyanskaya OG, Hunt DF (2007) Analysis of phosphorylation sites on proteins from Saccharomyces cerevisiae by electron transfer dissociation (ETD) mass spectrometry. Proc Natl Acad Sci U S A 104(7):2193–2198. Scholar
  200. 200.
    Hagen JB (2000) The origins of bioinformatics. Nat Rev Genet 1(3):231–236. Scholar
  201. 201.
    Colinge J, Bennett KL (2007) Introduction to computational proteomics. PLoS Comput Biol 3(7):e114. Scholar
  202. 202.
    Perez-Iratxeta C, Andrade-Navarro MA, Wren JD (2007) Evolving research trends in bioinformatics. Brief Bioinform 8(2):88–95. Scholar
  203. 203.
    Zamanian-Azodi M, Rezaei-Tavirani M, Mortazavian A, Vafaee R, Rezaei-Tavirani M, Zali H, Soheili-Kashani M (2015) Application of proteomics in cancer study. Am J Cancer Sci 2:1–18Google Scholar
  204. 204.
    Ebert MP, Korc M, Malfertheiner P, Rocken C (2006) Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J Proteome Res 5(1):19–25. Scholar
  205. 205.
    Miller JC, Zhou H, Kwekel J, Cavallo R, Burke J, Butler EB, Teh BS, Haab BB (2003) Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3(1):56–63. Scholar
  206. 206.
    FDA-NIH (2016) BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. In: (MD) SS (ed) BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD)Google Scholar
  207. 207.
    Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93(14):1054–1061. Scholar
  208. 208.
    Cyll K, Ersvaer E, Vlatkovic L, Pradhan M, Kildal W, Avranden Kjaer M, Kleppe A, Hveem TS, Carlsen B, Gill S, Loffeler S, Haug ES, Waehre H, Sooriakumaran P, Danielsen HE (2017) Tumour heterogeneity poses a significant challenge to cancer biomarker research. Br J Cancer 117(3):367–375. Scholar
  209. 209.
    Baggerly KA, Morris JS, Coombes KR (2004) Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20(5):777–785. Scholar
  210. 210.
    Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, Streicher HZ, Butterfield LH, Thurin M (2016) Validation of biomarkers to predict response to immunotherapy in cancer: volume I - pre-analytical and analytical validation. J Immunother Cancer 4:76. Scholar
  211. 211.
    Goossens N, Nakagawa S, Sun X, Hoshida Y (2015) Cancer biomarker discovery and validation. Transl Cancer Res 4(3):256–269. Scholar
  212. 212.
    Selleck MJ, Senthil M, Wall NR (2017) Making meaningful clinical use of biomarkers. Biomark Insights 12:1177271917715236. Scholar
  213. 213.
    Zheng Y (2018) Study design considerations for cancer biomarker discoveries. J Appl Lab Med 3(2):282–289. Scholar
  214. 214.
    Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100(20):1432–1438. Scholar
  215. 215.
    Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101(21):1446–1452. Scholar
  216. 216.
    Watson RW, Kay EW, Smith D (2010) Integrating biobanks: addressing the practical and ethical issues to deliver a valuable tool for cancer research. Nat Rev Cancer 10(9):646–651. Scholar
  217. 217.
    Pepe MS, Li CI, Feng Z (2015) Improving the quality of biomarker discovery research: the right samples and enough of them. Cancer Epidemiol Biomarkers Prev 24(6):944–950. Scholar
  218. 218.
    Fraser GA, Meyer RM (2007) Biomarkers and the design of clinical trials in cancer. Biomark Med 1(3):387–397. Scholar
  219. 219.
    van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009. Scholar
  220. 220.
    Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. Scholar
  221. 221.
    Nguyen HG, Welty CJ, Cooperberg MR (2015) Diagnostic associations of gene expression signatures in prostate cancer tissue. Curr Opin Urol 25(1):65–70. Scholar
  222. 222.
    You YN, Rustin RB, Sullivan JD (2015) Oncotype DX((R)) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: a review of the evidence. Surg Oncol 24(2):61–66. Scholar
  223. 223.
    Colburn WA (2003) Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol 43(4):329–341. Scholar
  224. 224.
    Freidlin B, McShane LM, Korn EL (2010) Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 102(3):152–160. Scholar
  225. 225.
    Gosho M, Nagashima K, Sato Y (2012) Study designs and statistical analyses for biomarker research. Sensors (Basel) 12(7):8966–8986. Scholar
  226. 226.
    Sargent DJ, Conley BA, Allegra C, Collette L (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23(9):2020–2027. Scholar
  227. 227.
    Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A (2011) Integrating biomarkers in clinical trials. Expert Rev Mol Diagn 11(2):171–182. Scholar
  228. 228.
    Chakravarty AG, Rothmann M, Sridhara R (2011) Regulatory issues in use of biomarkers in oncology trials. Stat Biopharm Res 3(4):569–576. Scholar
  229. 229.
    Jenkins M, Flynn A, Smart T, Harbron C, Sabin T, Ratnayake J, Delmar P, Herath A, Jarvis P, Matcham J, Group PSIBSI (2011) A statistician’s perspective on biomarkers in drug development. Pharm Stat 10(6):494–507. Scholar
  230. 230.
    Kontos CK, Adamopoulos PG, Scorilas A (2015) Prognostic and predictive biomarkers in prostate cancer. Expert Rev Mol Diagn 15(12):1567–1576. Scholar
  231. 231.
    Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68(5):1331–1337. Scholar
  232. 232.
    Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G (2019) Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res 12(1):28. Scholar
  233. 233.
    Bhatti I, Patel M, Dennison AR, Thomas MW, Garcea G (2015) Utility of postoperative CEA for surveillance of recurrence after resection of primary colorectal cancer. Int J Surg 16:123–128. Scholar
  234. 234.
    Vallam KC, Guruchannabasavaiah B, Agrawal A, Rangarajan V, Ostwal V, Engineer R, Saklani A (2017) Carcinoembryonic antigen directed PET-CECT scanning for postoperative surveillance of colorectal cancer. Colorectal Dis 19(10):907–911. Scholar
  235. 235.
    Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–1703. Scholar
  236. 236.
    Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372(18):1689–1699. Scholar
  237. 237.
    Carson PE, Flanagan CL, Ickes CE, Alving AS (1956) Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124(3220):484–485. Scholar
  238. 238.
    Kalow W, Staron N (1957) On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Can J Biochem Physiol 35(12):1305–1320CrossRefGoogle Scholar
  239. 239.
    Evans DA, Manley KA, Mc KV (1960) Genetic control of isoniazid metabolism in man. Br Med J 2(5197):485–491. Scholar
  240. 240.
    Mahgoub A, Dring LG, Idle JR, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 310(8038):584–586. Scholar
  241. 241.
    Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HU (1980) Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol 17(2):153–155. Scholar
  242. 242.
    Vogel F (1959) Moderne Probleme der Humangenetik. In: Heilmeyer L, Schoen R, de Rudder B (eds) Ergebnisse der Inneren Medizin und Kinderheilkunde, vol 12. Springer, Berlin, Heidelberg. Scholar
  243. 243.
    EMEA (2002) Position paper on terminology in pharmacogenetics. Committee for proprietary medicinal products. European Agency for the Evaluation of Medicinal ProductsGoogle Scholar
  244. 244.
    Redekop WK, Mladsi D (2013) The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health 16(6 Suppl):S4–S9. Scholar
  245. 245.
    Salari P, Larijani B (2017) Ethical issues surrounding personalized medicine: a literature review. Acta Med Iran 55(3):209–217PubMedGoogle Scholar
  246. 246.
    Annas GJ (2014) Personalized medicine or public health? Bioethics, human rights, and choice. Revista Portuguesa de Saúde Pública 32(2):158–163. Scholar
  247. 247.
    Vogenberg FR, Isaacson Barash C, Pursel M (2010) Personalized medicine: part 1: evolution and development into theranostics. P T 35(10):560–576PubMedPubMedCentralGoogle Scholar
  248. 248.
    Chen R, Snyder M (2013) Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med 5(1):73–82. Scholar
  249. 249.
    Ginsburg GS, Phillips KA (2018) Precision medicine: from science to value. Health Aff (Millwood) 37(5):694–701. Scholar
  250. 250.
    Alyass A, Turcotte M, Meyre D (2015) From big data analysis to personalized medicine for all: challenges and opportunities. BMC Med Genomics 8:33. Scholar
  251. 251.
    Popa ML, Albulescu R, Neagu M, Hinescu ME, Tanase C (2019) Multiplex assay for multiomics advances in personalized-precision medicine. J Immunoassay Immunochem 40(1):3–25. Scholar
  252. 252.
    Sharrer GT (2017) Personalized medicine: ethical aspects. Methods Mol Biol 1606:37–50. Scholar
  253. 253.
    Badzek L, Henaghan M, Turner M, Monsen R (2013) Ethical, legal, and social issues in the translation of genomics into health care. J Nurs Scholarsh 45(1):15–24. Scholar
  254. 254.
    Joly Y, Saulnier KM, Osien G, Knoppers BM (2014) The ethical framing of personalized medicine. Curr Opin Allergy Clin Immunol 14(5):404–408. Scholar
  255. 255.
    Salari K, Watkins H, Ashley EA (2012) Personalized medicine: hope or hype? Eur Heart J 33(13):1564–1570. Scholar
  256. 256.
    Kurnat-Thoma EL (2011) Genetics and genomics: the scientific drivers of personalized medicine. Annu Rev Nurs Res 29:27–54CrossRefGoogle Scholar
  257. 257.
    Martincorena I, Campbell PJ (2015) Somatic mutation in cancer and normal cells. Science 349(6255):1483–1489. Scholar
  258. 258.
    Cocca M, Bedognetti D, La Bianca M, Gasparini P, Girotto G (2016) Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations. J Transl Med 14:22. Scholar
  259. 259.
    Tavares P, Dias L, Palmeiro A, Rendeiro P, Tolias P (2011) Single-test parallel assessment of multiple genetic disorders. Pers Med 8(3):375–379. Scholar
  260. 260.
    Roth M, Keeling P, Smart D (2010) Driving personalized medicine: capturing maximum net present value and optimal return on investment. Pers Med 7(1):103–114. Scholar
  261. 261.
    Steffen JA, Steffen JS (2013) Driving forces behind the past and future emergence of personalized medicine. J Pers Med 3(1):14–22. Scholar
  262. 262.
    Goldberger JJ, Buxton AE (2013) Personalized medicine vs guideline-based medicine. JAMA 309(24):2559–2560. Scholar
  263. 263.
    Chen R, Snyder M (2012) Systems biology: personalized medicine for the future? Curr Opin Pharmacol 12(5):623–628. Scholar
  264. 264.
    Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK, Tangrea MA (2009) Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev Mol Diagn 9(5):455–467. Scholar
  265. 265.
    Pardanani A, Wieben ED, Spelsberg TC, Tefferi A (2002) Primer on medical genomics. Part IV: expression proteomics. Mayo Clin Proc 77(11):1185–1196. Scholar
  266. 266.
    Haga SB, Beskow LM (2008) Ethical, legal, and social implications of biobanks for genetics research. Adv Genet 60:505–544. Scholar
  267. 267.
    Chalmers D (2011) Genetic research and biobanks. Methods Mol Biol 675:1–37. Scholar
  268. 268.
    Jamal L, Sapp JC, Lewis K, Yanes T, Facio FM, Biesecker LG, Biesecker BB (2014) Research participants’ attitudes towards the confidentiality of genomic sequence information. Eur J Hum Genet 22(8):964–968. Scholar
  269. 269.
    Caulfield T, McGuire AL, Cho M, Buchanan JA, Burgess MM, Danilczyk U, Diaz CM, Fryer-Edwards K, Green SK, Hodosh MA, Juengst ET, Kaye J, Kedes L, Knoppers BM, Lemmens T, Meslin EM, Murphy J, Nussbaum RL, Otlowski M, Pullman D, Ray PN, Sugarman J, Timmons M (2008) Research ethics recommendations for whole-genome research: consensus statement. PLoS Biol 6(3):e73. Scholar
  270. 270.
    Goh AM, Chiu E, Yastrubetskaya O, Erwin C, Williams JK, Juhl AR, Paulsen JS, Group IR-HIOTHS (2013) Perception, experience, and response to genetic discrimination in Huntington’s disease: the Australian results of The International RESPOND-HD study. Genet Test Mol Biomarkers 17(2):115–121. Scholar
  271. 271.
    Matloff ET, Bonadies DC, Moyer A, Brierley KL (2014) Changes in specialists’ perspectives on cancer genetic testing, prophylactic surgery and insurance discrimination: then and now. J Genet Couns 23(2):164–171. Scholar
  272. 272.
    Pierce JD, Fakhari M, Works KV, Pierce JT, Clancy RL (2007) Understanding proteomics. Nurs Health Sci 9(1):54–60. Scholar
  273. 273.
    Carlson RJ (2009) The disruptive nature of personalized medicine technologies: implications for the health care system. Public Health Genomics 12(3):180–184. Scholar
  274. 274.
    Celis JE, Kruhøffer M, Gromova I, Frederiksen C, Østergaard M, Thykjaer T, Gromov P, Yu J, Pálsdóttir H, Magnusson N, Ørntoft TF (2000) Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett 480(1):2–16. Scholar
  275. 275.
    Agyeman AA, Ofori-Asenso R (2015) Perspective: does personalized medicine hold the future for medicine? J Pharm Bioallied Sci 7(3):239–244. Scholar
  276. 276.
    Mosca R, Ceol A, Aloy P (2013) Interactome3D: adding structural details to protein networks. Nat Methods 10(1):47–53. Scholar
  277. 277.
    Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, Ziegler E, Butzmann L, Gessulat S, Marx H, Mathieson T, Lemeer S, Schnatbaum K, Reimer U, Wenschuh H, Mollenhauer M, Slotta-Huspenina J, Boese JH, Bantscheff M, Gerstmair A, Faerber F, Kuster B (2014) Mass-spectrometry-based draft of the human proteome. Nature 509(7502):582–587. Scholar
  278. 278.
    Hanash S, Taguchi A (2010) The grand challenge to decipher the cancer proteome. Nat Rev Cancer 10(9):652–660. Scholar
  279. 279.
    Khan SR, Khurshid Z, Akhbar S, Moin FS (2016) Advances of salivary proteomics in Oral Squamous Cell Carcinoma (OSCC) detection: an update. Proteomes 4(4).
  280. 280.
    Shah FD, Begum R, Vajaria BN, Patel KR, Patel JB, Shukla SN, Patel PS (2011) A review on salivary genomics and proteomics biomarkers in oral cancer. Indian J Clin Biochem 26(4):326–334. Scholar
  281. 281.
    Behjati S, Haniffa M (2017) Genetics: taking single-cell transcriptomics to the bedside. Nat Rev Clin Oncol 14(10):590–592. Scholar
  282. 282.
    MacBeath G (2002) Protein microarrays and proteomics. Nat Genet 32(Suppl):526–532. Scholar
  283. 283.
    Celis JE, Gromov P (2003) Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3(1):9–15. Scholar
  284. 284.
    Vaidyanathan G (2012) Redefining clinical trials: the age of personalized medicine. Cell 148(6):1079–1080. Scholar
  285. 285.
    Sanchez JC, Couté Y, Allard L, Lescuyer P, Hochstrasser DF (2007) Biomedical applications of proteomics. Principles and practice. Springer, Berlin, Heidelberg, Proteome Research.
  286. 286.
    Barbosa EB, Vidotto A, Polachini GM, Henrique T, Marqui AB, Tajara EH (2012) Proteomics: methodologies and applications to the study of human diseases. Rev Assoc Med Bras (1992) 58(3):366–375. Scholar
  287. 287.
    Jain KK (2008) Recent advances in nanooncology. Technol Cancer Res Treat 7(1):1–13. Scholar
  288. 288.
    Kopf E, Zharhary D (2007) Antibody arrays--an emerging tool in cancer proteomics. Int J Biochem Cell Biol 39(7–8):1305–1317. Scholar
  289. 289.
    Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, Wang H, Li Y, Tan W (2008) Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res 7(5):2133–2139. Scholar
  290. 290.
    Hardouin J, Lasserre JP, Sylvius L, Joubert-Caron R, Caron M (2007) Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann N Y Acad Sci 1107:223–230. Scholar
  291. 291.
    Voduc D, Kenney C, Nielsen TO (2008) Tissue microarrays in clinical oncology. Semin Radiat Oncol 18(2):89–97. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Department of Biological SciencesNational University of Medical SciencesRawalpindiPakistan

Personalised recommendations